Platform Technology
Flexible mRNA and plasmid DNA platforms built to scale with your program, from early research through clinical readiness.
SCALABLE, GMP-READY RNA SOLUTIONS
Australia’s Advanced mRNA Manufacturing Partner — From Discovery to GMP Clinical Supply
End-to-End Support
One partner from sequence design to release-tested material: process development, manufacturing, and analytics under one roof.
Top Talent
A multidisciplinary team spanning nucleic acid chemistry, molecular biology, and process development stands behind every project.
Tax Incentive
As an Australian manufacturer, your eligible R&D spend with Southern RNA may qualify under the Australian Government’s R&D Tax Incentive.
01
/
04
Biotech and Pharma R&D
Researchers and biotechnology companies use Southern RNA’s plasmid DNA and mRNA production platforms to generate high-quality raw materials for gene expression studies, vaccine design, and therapeutic candidate evaluation. This includes capped, modified mRNA and traceable pDNA templates for in vitro and in vivo applications.
02
/
04
Preclinical Development
Preclinical programs benefit from scalable production of research and GMP-aligned grade nucleic acids as they advance toward translational milestones. Southern RNA’s process development and analytical services help ensure consistency, purity, and suitability for later stages of evaluation.
03
/
04
Clinical Supply Enablement
Biopharmaceutical developers preparing for early clinical studies (FIH through Phase I/II) rely on Southern RNA’s GMP-capable workflows to produce clinical-appropriate drug substance. This includes plasmid DNA for viral vector manufacturing and mRNA for vaccines or cell therapies, with quality documentation supporting regulatory needs.
04
/
04
Analytical and Quality Testing
Scientists and quality teams use Southern RNA’s comprehensive analytical platform to characterise nucleic acid products, support method development, and validate stability and release assays. This underpins confidence in product performance and regulatory compliance throughout development.
SERVICES
RNA Development & Manufacturing Services
Southern RNA provides plasmid DNA and mRNA services, merging flexible manufacturing with advanced analytics. Our team supports scalable, high-quality nucleic acid production for therapeutic programs.
Develop & Manufacture
We provide plasmid DNA (pDNA) and mRNA production using flexible platforms that deliver high-quality R&D and GMP- aligned grade materials at scalable volumes.
Test & Release
We provide a comprehensive nucleic acid analytical platform, supported by the deep expertise and experience of our multidisciplinary scientific team.
PRODUCTS
High-Quality RNA & DNA Solutions
Southern RNA provides high-quality plasmid DNA and mRNA products for research and clinical applications. Our scalable production ensures consistent quality and performance, helping scientists accelerate RNA-based therapies.
Co Cap™ A
Discover our co-transcriptional capping reagent for mRNA and lower the cost of your IVT.
WHY US
01
Phase-appropriate, scale-flexible CDMO platform
Integrated mRNA manufacturing and analytical testing processes designed to scale efficiently from early development to clinical readiness.
02
Phase-Appropriate Quality Systems
Robust, stage-aligned quality documentation and controls that support development, tech transfer, and regulatory progression.
03
Time-Critical Delivery
Streamlined workflows and responsive project management to meet tight timelines without compromising quality or compliance.
04
Deep Technical Expertise
Hands-on scientific support across nucleic acid design, synthesis, purification, and advanced analytical testing.
05
Regulatory-Focused Support
Comprehensive documentation and guidance aligned with clinical and regulatory expectations at every phase.
CLINICAL TRIAL
Designed for Regulatory Progression
Australia offers a world-class environment for early-phase clinical studies, with GMP-capable facilities, experienced scientific teams, and comprehensive analytical capabilities ensuring high-quality plasmid DNA and mRNA at scale.
With clear regulatory frameworks, robust documentation standards, and streamlined submission processes, Australia provides a reliable pathway from research to first-in-human trials, helping de-risk timelines and accelerate progression from lab to clinic on the global stage.
PLATFORM OVERVIEW
Advanced Platforms Powering RNA Development
Southern RNA’s platforms combine scalable manufacturing and analytics for high-quality plasmid DNA and mRNA production. Our technologies accelerate development while ensuring control and quality for clinical progression.
02.
Production of high-quality plasmid DNA for use as IVT template and as starting material for advanced therapy programs. Linearisation, purification, and quality control are scaled to your development stage.
03.
Co-transcriptional capping using Southern RNA’s Co Cap™ A reagents delivers high capping efficiency in a single IVT step, lowering cost and complexity versus enzymatic post-capping.
04.
A comprehensive nucleic acid analytical suite covering identity, purity, integrity, and content, supporting method development, in-process control, and release and stability testing.
05.
Systematic optimisation of IVT and purification processes for reproducibility and yield, with efficient scale-up from milligram research quantities to gram-scale batches.
TESTIMONIALS
Voices of Confidence
Hear from partners and collaborators who’ve advanced their programs with Southern RNA.
“Partnering with Southern RNA dramatically accelerated our timeline from concept to GMP-ready material. Their team’s expertise and responsiveness were invaluable.”
Clinical Development Lead
Biotech Partner
Latest News
Explore expert articles, case studies, and news that decode the science and trends shaping RNA therapeutics.
In the press / Latest Publications
February 23, 2026
World-First Paediatric Brain Cancer Vaccine – Supported by Southern RNA
SEE MORE
In the press / Latest Publications
December 23, 2025
Southern RNA opens at the Gold Coast Health and Knowledge Precinct
SEE MORE
In the press / Latest Publications
October 14, 2025